ONCOGEN THERAPEUTICS INC. SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS REPORT ON MAJOR INVESTIGATIVE TREADS

A 73% stock price drop in less than 3 months following a chronology of public statements questioned by the U.S. Food and Drug Administration, an ongoing FINRA investigation possibly referable to the Securities and Exchange Commission for potential insider trading concerns, and an employee whistleblo...